|Articles|October 1, 2018

Does being an orphan speed up FDA approval?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Can AI Help Solve the Issue of High Failure Rates in Clinical Trials?

ByMike Hollan,Angela Schwab

January 9th 2026

The Situation We Faced: Aaron Cowley, CSO, Recipharm Advanced Bio, Discusses Vision to Cut Biomanufacturing Timelines, Transform Continuous Manufacturing

ByChris Spivey,Aaron Cowley

January 8th 2026

Image Credit: Adobe Stock Images/KRISTINA KUPTSEVICH

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

ByDavy James

January 8th 2026

Pharmaceutical Executive Daily: FDA Limits Regulations of Non-Medical Fitness Devices

ByNicholas Jacobus

January 8th 2026

FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz

ByNicholas Jacobus

January 8th 2026

Does being an orphan speed up FDA approval?

Newsletter

Related Content

Can AI Help Solve the Issue of High Failure Rates in Clinical Trials?

The Situation We Faced: Aaron Cowley, CSO, Recipharm Advanced Bio, Discusses Vision to Cut Biomanufacturing Timelines, Transform Continuous Manufacturing

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

Pharmaceutical Executive Daily: FDA Limits Regulations of Non-Medical Fitness Devices

FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz

Trending on PharmExec

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences

FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices

Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model

GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications